Table of Contents:
I. Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R01 Clinical Trial Not Allowed) RFA-DA-20-023
II. Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (Clinical Trial Optional) PAR-19-039 and PAR-19-040
III. Funding Opportunity: Methods to Improve Reproducibility of iPSC Derivation, Growth, and Differentiation RFA-GM-19-001
IV. Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional)
PAR-19-310
V. Notice of Special Interest (NOSI): The Application of Big Data Analytics to Drug Abuse Research NOT-DA-19-041
VI. Leveraging Big Data Science to Elucidate the Neural Mechanisms of Addiction and Substance Use Disorder (R01 – Clinical Trials Not Allowed) RFA-DA-20-006
VII. Leveraging Big Data Science to Elucidate the Neural Mechanisms of Addiction and Substance Use Disorder (R21 – Clinical Trials Not Allowed) RFA-DA-20-007
I. Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R01 Clinical Trial Not Allowed) RFA-DA-20-023
Application Deadline: November 12, 2019
Description:
This Funding Opportunity Announcement supports projects aimed at the elucidation of microglia-neuronal pathophysiological mechanisms of HAND in the presence and absence of substances of abuse, using cerebral organoids and microglia derived from human iPSCs. It is expected that the latest 3D technology will be used to create the cerebral organoids. Investigators are encouraged to exploit state of-art technologies including Omics assays, genomic editing tools such as CRISPR, and single cell analysis and imaging approaches to address outstanding questions regarding molecular regulation of persistent HIV (e.g. latency or reservoirs) in the context of chronic substance use or substance use disorders (SUD). Applications focused solely on alcohol exposure will be considered non-responsive to this FOA.
II. Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (Clinical Trial Optional) PAR-19-039 and PAR-19-040
Application deadline: September 10, 2019.
Description:
NIDA is announcing a high priority interest in receiving grant applications for the discovery and development of treatments to prevent and treat opioid-induced respiratory depression and overdose. Applications may focus on the development of new chemical entities, biologics, assay development, animal model development, new formulations, or combinations of medications that hold promise for the treatment of opioid overdose. A wide variety of treatment strategies will be considered including, but are not limited to, longer acting opioid-receptor antagonists, opioid sequestration agents and/or respiratory stimulants.
Please contact Kris Bough (boughk@mail.nih.gov) with questions.
III. Funding Opportunity: Methods to Improve Reproducibility of iPSC Derivation, Growth, and Differentiation RFA-GM-19-001
Application Due date:
January 6, 2020, by 5:00 PM local time of applicant organization.
We want to let you know about a funding opportunity that may be of interest to you or others in your network. We are seeking Small Business Innovation Research (SBIR) applications to develop methods that improve the reproducibility of human induced pluripotent stem cell (iPSC) derivation, growth, and differentiation (RFA-GM-19-001). As you probably know, realizing the full potential of human iPSCs for both research and clinical practice has been limited by the significant variability in reprogramming efficiency, differentiation potential, and cell growth and stability. Overall, 11 NIH Institutes and centers intend to commit funds, with an estimated 25 awards. We hope this broad reach will help us develop novel, reliable, and cost-effective methods to standardize and increase the utility and reproducibility of iPSCs at all stages, from their derivation to their research and clinical uses. Applications will be accepted from December 6, 2019 through January 6, 2020.
IV. Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional)
PAR-19-310
Application Deadline: September 16, 2019
Description:
This Funding Opportunity will use a NIH Small Research Grant (R03) award mechanism designed to support innovation in development or use of new paradigms or theories to study affective, cognitive and behavioral processes contributing to substance use disorders (SUD). Proposals focused on new hypotheses, models, and/or methods, in both preclinical and clinical SUD research, are solicited. The B/START R03 is intended for recently-independent investigators with expertise in behavioral science as well as established investigators who are using behavioral science approaches to SUD for the first time. B/START-supported projects are expected to produce a coherent set of preliminary findings that would inform the design of a more complete study and serve as preliminary data supporting feasibility or scientific rationale in an R01, R21 or similar application.
V. Notice of Special Interest (NOSI): The Application of Big Data Analytics to Drug Abuse Research NOT-DA-19-041
Expiration Date: January 8, 2022
Standard Application Dates Apply.
Description: The purpose of this Notice is to inform potential applications to the National Institute on Drug Abuse (NIDA) to encourage grant applications that will use ‘big data’ analytics to reveal deeper or novel insights into the biological and behavioral processes associated with substance use and addiction by developing more powerful analytical methods and visualization tools that can help capture the richness of different data types and across scales of analysis; including molecular, clinical, and electronic health records. Applications should develop and/or utilize computational approaches for analyzing large, complex datasets acquired from drug addiction research.
VI. Leveraging Big Data Science to Elucidate the Neural Mechanisms of Addiction and Substance Use Disorder (R01 – Clinical Trials Not Allowed) RFA-DA-20-006
Application Deadline: November 14, 2019
Description:
The purpose of this FOA is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis. It is expected that with the development and application of novel computational, bioinformatics, statistical, and analytical approaches, previously inaccessible insights will reveal new aspects of addiction biology.
VII. Leveraging Big Data Science to Elucidate the Neural Mechanisms of Addiction and Substance Use Disorder (R21 – Clinical Trials Not Allowed) RFA-DA-20-007
Application Deadline: November 14, 2019
Description: The purpose of this FOA is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis. It is expected that with the development and application of novel computational, bioinformatics, statistical, and analytical approaches, previously inaccessible insights will reveal new aspects of addiction biology.
VIII. Leveraging Big Data Science to Elucidate the HIV Activity and Interaction with Substance Use Disorder (R01 – Clinical Trials Not Allowed) RFA-DA-20-008
Application Deadline: November 14, 2019
Description:
The purpose of this FOA is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis through big data science approaches. It is expected that the development and application of novel computational, bioinformatics, statistical, and analytical approaches can be leveraged to reveal the effects of the interaction of the HIV virus and drugs of abuse on viral activity, latency, and disease progression, as well as new aspects of addiction biology.
IX. Leveraging Big Data Science to Elucidate the HIV Activity and Interaction with Substance Use Disorder (R21 – Clinical Trials Not Allowed) RFA-DA-20-009
Application Deadline: November 14, 2019
Description:
The purpose of this FOA is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis through big data science approaches. It is expected that the development and application of novel computational, bioinformatics, statistical, and analytical approaches can be leveraged to reveal the effects of the interaction of the HIV virus and drugs of abuse on viral activity, latency, and disease progression, as well as new aspects of addiction biology.
The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov 301-435-1309
No comments:
Post a Comment